Pfizer said on Tuesday it is reducing its U.S. sales staff as it expects doctors and other health-care providers to want fewer face-to-face interactions with salespeople after the Covid-19 pandemic ends.

It comes at a time when the company anticipates more than $80B in revenue for 2021, thanks to the strong sales of Covid-19, the vaccine that it created with Germany. BioNTech. Albert Bourla Chief Executive of Pfizer said that this would result in record sales at a pharmaceutical company.

In a statement, the company stated that they are moving to be a more focused and creative biopharma company. They also plan on changing how they interact with health professionals in the digital age.

We will make some adjustments to our workforce in order to have the appropriate expertise and resources to support our changing needs.

It did not say how many jobs were being eliminated.

Sources close to the situation said that Pfizer would be eliminating around 100 positions. A source claimed that Pfizer plans to create about half the jobs by adding new roles in various areas.

According to Reuters, Pfizer thinks that around half the interactions they have with pharmaceutical companies will be distant in the future.

Analyst estimates predict that Pfizer will see its revenue rise even more this year, reaching $100 billion.

The Covid-19 vaccine, and the new oral Covid-19 treatment Paxlovid are likely to account for around half the 2022 company sales.

Paxlovid is being sold direct to the governments for immediate use.